ArticleACS nano2010
Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo.
Article in ACS nano, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery.Nature communications · 2024Pooled it
- Gadolinium Nanoparticles: Emerging Platforms Beyond Imaging for Drug Delivery and Theranostics.Pharmaceutics · 2026Review
- Tumor radiosensitization with gold nanoparticles: evolving strategies to improve tumoral gold uptake and catalyze future clinical translation.ACS nano medicine · 2026Article
- Reticuloendothelial system blockade does not enhance siRNA-LNP circulation or tumor accumulation in mice.International journal of pharmaceutics: X · 2025Article
- Understanding nanoparticle-liver interactions in nanomedicine.Expert opinion on drug delivery · 2024Review
- Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles.Advanced functional materials · 2024Article
- mRNA as a medicine in nephrology: the future is now.Clinical kidney journal · 2023Review
- Mechano-boosting nanomedicine antitumour efficacy by blocking the reticuloendothelial system with stiff nanogels.Nature communications · 2023Article
- Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials.Exploration (Beijing, China) · 2023Review
- Pancreatic tumor microenvironmental acidosis and hypoxia transform gold nanorods into cell-penetrant particles for potent radiosensitization.Science advances · 2022Article
- Review
- A Nanoparticle's Journey to the Tumor: Strategies to Overcome First-Pass Metabolism and Their Limitations.Cancers · 2022Review
- Boosting nanomedicine performance by conditioning macrophages with methyl palmitate nanoparticles.Materials horizons · 2021Article
- Sphingosine kinase 1 regulates HMGB1 translocation by directly interacting with calcium/calmodulin protein kinase II-δ in sepsis-associated liver injury.Cell death & disease · 2020Article
- A combined "eat me/don't eat me" strategy based on extracellular vesicles for anticancer nanomedicine.Journal of extracellular vesicles · 2020Article
- Review
- Clinical Cancer Nanomedicine.Nano today · 2019Article
- Effect of removing Kupffer cells on nanoparticle tumor delivery.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Strategies for improving drug delivery: nanocarriers and microenvironmental priming.Expert opinion on drug delivery · 2017Review
- Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts.Science translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Nonspecific sequestration of nanoparticles by the reticulo-endothelial system (RES) results in the degradation of image quality of nanoparticle-based imaging. We demonstrate that gadolinium chloride (GdCl3) pretreatment inactivates RES macrophages, thereby increasing circulatory time and amplifying the tumor-specific signal of conjugated nanoparticles in vivo. The experimental results were validated using compartmental modeling, and the rate parameters for the observed kinetics pattern were estimated. This pretreatment strategy could have broad applicability across biomedical applications utilizing theranostic nanoparticles that are sequestered by the RES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.